Eagle Health’s revenues have grown at 17% CAGR from FY2015 to FY2017, with FY2017 constant currency revenues of $93.6m, a 52% gross profit margin and double digit growth in key product categories. Eagle Health listed in the ASX in mid 2017 to build on a five year strategy of driving accelerated growth in China and acquiring or licensing quality Australian products or ingredients for sale into its strong Chinese network. The Company believes there is strong continued growth potential and that it is well positioned as compared to many Australian companies seeking to penetrate China.
Eagle Health targets the mid-market for affordable mainstream and over the counter consumer health in China through its deep and proven distribution network of 274 distributors with penetration into pharmacies, supermarkets, own brand stores, and health food stores.
Eagle Health has sales in 26 provinces in China with largest proportion of sales in Guangdong (24%), the most populated province in China, which has overtaken sales in Eagle Health’s home province of Fujian (23%).